Pharmazz and Sun Pharma Enter into Licensing Agreement to Commercialize Tyvalzi (Sovateltide) in India for Cerebral Ischemic Stroke
- Under the terms of the agreement, Sun Pharma received commercialization rights of sovateltide in India under the brand name Tyvalzi, and in exchange, Pharmazz will receive upfront and milestone payments along with royalties
- Tyvalzi (sovateltide), is a selective endothelin B receptor agonist, neuronal progenitor cell therapy available for the treatment of acute cerebral ischemic stroke by inducing neurovascular remodeling
- It can be administered for up to 24hrs. after the onset of symptoms and produced clinical improvement in neurological outcomes at 90days post-treatment as measured by the NIHSS, mRS, and B.I. scales
Ref: Globenewswire | Image: Sun Pharma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.